Boston Scientific (BSX), Silk Road Merger Delayed for Review
Boston Scientific (BSX) withdraws its premerger notification and report form to give the U.S. FTC more time to review the proposed acquisition of Silk Road Medical.
Buy 5 Surging Old Economy Stocks to Tap Market Rally
Five old economy stocks with strong near-term potential are: NEM, GE, PFE, PGR, BSX.
Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
3 Reasons Why Growth Investors Shouldn't Overlook Boston Scientific (BSX)
Boston Scientific (BSX) could produce exceptional returns because of its solid growth attributes.
Boston Scientific (BSX) Rides on Global Growth, Buyouts
Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.
3 Record-Breaking Stocks With More Upside Ahead
2024 has been a great year for U.S. indices, with the benchmark S&P 500 posting new all-time highs 38 times so far. The rally has been primarily driven by the tech sector, focusing on artificial intelligence (AI).
Boston Scientific (BSX) Q2 Earnings Beat, Organic Sales Rise
Boston Scientific (BSX) registers a strong year-over-year improvement in sales, indicating solid market share gains in legacy businesses across all geographic regions.
Boston Scientific Profit and Sales Are Boosted by Cardiovascular Device Demand
Boston Scientific (BSX) posted an increase in second-quarter earnings and sales on the back of growing demand for its heart devices.
Boston Scientific Corporation (BSX) Q2 2024 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX ) Q2 2024 Earnings Conference Call July 24, 2024 8:00 AM ET Company Participants Jon Monson - SVP, IR Michael F. Mahoney - Chairman and CEO Daniel J.
Boston Scientific (BSX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Boston Scientific (BSX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Boston Scientific (BSX) Surpasses Q2 Earnings and Revenue Estimates
Boston Scientific (BSX) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.53 per share a year ago.
Boston Scientific raises annual profit forecast on heart devices demand
Boston Scientific raised its full-year profit forecast on Wednesday on the back of strong demand for its heart devices, sending the medical device maker's shares up 2% in premarket trading.
